Open AccessThe First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
Author(s) -
Joely KaufmanJanette,
Rui L. Avelar,
Brian S. Biesman,
Zoe Diana Draelos,
John E. Gross,
Derek Jones,
Mary P. Lupo,
Corey S. Maas,
Joel Schlessinger,
Ava Shamban,
Hema Sundaram,
Susan Weinkle,
V. Leroy Young
Publication year - 2021
Publication title -
aesthetic surgery journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.528
H-Index - 58
eISSN - 1527-330X
pISSN - 1090-820X
DOI - 10.1093/asj/sjaa383
Subject(s) - medicine , adverse effect , multicenter study , eyelid , ptosis , open label study , surgery , randomized controlled trial
PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom